Skip to main content
Log in

Benefit–Risk Assessment of Diacerein in the Treatment of Osteoarthritis

  • Review Article
  • Published:
Drug Safety Aims and scope Submit manuscript


Osteoarthritis (OA) is the leading musculoskeletal cause of disability. Despite this, there is no consensus on the precise definition of OA and what is the best treatment to improve symptoms and slow disease progression. Current pharmacological treatments include analgesics, non-steroidal anti-inflammatory drugs (NSAIDs) and cyclooxygenase (COX) inhibitors. None of those treatments are disease-modifying agents that target the core pathological processes in OA. Diacerein, a semi-synthetic anthraquinone derivative, inhibits the interleukin-1-beta (IL-1β) cytokine which, according to animal studies, plays a key role in the pathogenesis of OA. Diacerein was synthesized in 1980 and licensed in some European Union and Asian countries for up to 20 years. It has shown modest efficacy and acceptable tolerability in a number of trials of low to moderate quality. Early this year, the European Medicines Agency (EMA) conducted a review and restricted the use of diacerein-containing medicines. This was because of major concerns about the frequency and severity of diarrhoea and liver disorders in OA patients. In addition, the EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) questioned the limited clinical benefits of diacerein, which, in their view, did not outweigh its risks. The aim of this review is to provide a benefit–risk assessment of diacerein in the treatment of OA, based on asystematic evaluation of the published efficacy and safety data. Overall, there is evidence that diacerein is modestly effective for symptoms and possibly for radiographic changes, but this needs to be balanced against higher rates of gastrointestinal toxicity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others


  1. Jones G. Sources of pain in osteoarthritis: implications for therapy. Int J Clin Rheumatol. 2013;8:335–46.

    Article  CAS  Google Scholar 

  2. Fidelix TS, Macedo CR, Maxwell LJ, Fernandes Moça Trevisani V. Diacerein for osteoarthritis. Cochrane Database Syst Rev. 2014;2:CD005117.

  3. Zhang W, Nuki G, Moskowitz RW, et al. OARSI recommendations for the management of hip and knee osteoarthritis: part III. Changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage. 2010;18:476–99.

    Article  CAS  PubMed  Google Scholar 

  4. Louthrenoo W, Nilganuwong S, Aksaranugraha S, Asavatanabodee P, Saengnipanthkul S, Thai Study Group. The efficacy, safety and carry-over effect of diacerein in the treatment of painful knee osteoarthritis: a randomised, double-blind, NSAID-controlled study. Osteoarthritis Cartilage. 2007;15(6):605–14.

    Article  CAS  PubMed  Google Scholar 

  5. Pavelka K, Trc T, Karpas K, Vítek P, Sedlácková M, Vlasáková V, Böhmová J, Rovenský J. The efficacy and safety of diacerein in the treatment of painful osteoarthritis of the knee: a randomized, multicenter, double-blind, placebo-controlled study with primary end points at two months after the end of a three-month treatment period. Arthritis Rheum. 2007;56(12):4055–64.

    Article  CAS  PubMed  Google Scholar 

  6. Kirkham B. Interleukin-1, immune activation pathways, and different mechanisms in osteoarthritis and rheumatoid arthritis. Ann Rheum Dis. 1991;50:395–400.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  7. Stannus O, Jones G, Cicuttini F, et al. Circulating levels of IL-6 and TNF-α are associated with knee radiographic osteoarthritis and knee cartilage loss in older adults. Osteoarthritis Cartilage. 2010;18:1441–8.

    Article  CAS  PubMed  Google Scholar 

  8. Pelletier JP, Yaron M, Haraoui B, et al. Efficacy and safety of diacerein in osteoarthritis of knee: a double-blind, placebo controlled trial. The Diacerein Study Group. Arthritis Rheum. 2000;43(10):2339–48.

    Article  CAS  PubMed  Google Scholar 

  9. Dougados M, Nguyen M, Berdah L, et al. Evaluation of structure modifying effect of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial evaluation of the chondromodulating effect of diacerein in osteoarthritis of the hip. Arthritis Rheum. 2001;44(11):2539–47.

    Article  CAS  PubMed  Google Scholar 

  10. Lane NE, Brandt K, Hawker G, et al. OARSI–FDA initiative: defining the disease state of osteoarthritis. Osteoarthritis Cartilage. 2011;19:478–82.

    Article  CAS  PubMed  Google Scholar 

  11. Spencer CM, Wilde MI. Diacerein. Drugs. 1997;53(1):98–106.

    Article  CAS  PubMed  Google Scholar 

  12. Pham T, Le Henanff A, Ravaud P, Dieppe P, Paolozzi L, Dougados M. Evaluation of the symptomatic and structural efficacy of a new hyaluronic acid compound, NRD101, in comparison with diacerein and placebo in a 1 year randomised controlled study in symptomatic knee osteoarthritis. Ann Rheum Dis. 2004;63(12):1611–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

Download references


No sources of funding were used in the preparation of this review. Elena Panova and Graeme Jones have no conflicts of interest that are directly relevant to the content of the review.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Graeme Jones.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Panova, E., Jones, G. Benefit–Risk Assessment of Diacerein in the Treatment of Osteoarthritis. Drug Saf 38, 245–252 (2015).

Download citation

  • Published:

  • Issue Date:

  • DOI: